Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice Regarding Change in Major Shareholder and Largest Shareholder
[Summary] Nxera Announces Buyback and Consent Solicitation for Existing Convertible Bonds
Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan
Nxera Announces Focused Restructuring to Enhance Path to Profitability
Consolidated Financial Results for the Nine months Ended September 30, 2025 (IFRS)
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
Nxera Pharma, Jan-Sep (Cumulative 3Q) Net Income Loss Widens, Jul-Sep Net Income Turns to Loss
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Nxera Pharma, Apr-Jun (2Q) Net Income Loss Widens
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Consolidated Financial Results for the Six months Ended June 30, 2025 (IFRS)
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Nxera to Receive US$4.8 mn in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel OX2R Agonist
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568